Share of cannabidiol clinical trials worldwide by condition 2010-2023
Between 2010 and 2023, around 30 percent of clinical trials involving cannabidiol (CBD) targeted pain. Epilepsy was the second most targeted medical condition with around 27 percent of trials. This statistic shows the percentage of clinical trials involving CBD worldwide between 2010 and 2023, by targeted medical condition.